EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identificat...

Description complète

Détails bibliographiques
Auteurs principaux: Florent Baty, Sacha Rothschild, Martin Früh, Daniel Betticher, Cornelia Dröge, Richard Cathomas, Daniel Rauch, Oliver Gautschi, Lukas Bubendorf, Susanne Crowe, Francesco Zappa, Miklos Pless, Martin Brutsche, Swiss Group for Clinical Cancer Research
Format: Article
Langue:English
Publié: Public Library of Science (PLoS) 2013-01-01
Collection:PLoS ONE
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24039832/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24039832/?tool=EBI

Documents similaires